Table 3.
Assessment of the streamlined intervention at original control sites: on HHC identified and starting TPT.
| HHC identified at control sites: | Estimates (95% CI) of differences in rates between phase 4 and: |
|||
|---|---|---|---|---|
| Phase 1 | Phase 2 | Phase 3 | Phase 1,2,3 | |
| All countries (n = 8 sites)a | ||||
| Phase 4 compared to: | 248 (130, 365) | 270 (123, 417) | 33 (−32, 97) | 212 (104, 320) |
| LMIC only (n = 6 sites)a | ||||
| Phase 4 compared to: | 260 (143, 378) | 291 (157, 425) | 48 (−25, 121) | 229 (130, 328) |
|
HHC starting TPT at control sites: |
Phase 1 |
Phase 2 |
Phase 3 |
Phase 1,2,3 |
| All countries (n = 8 sites)b | ||||
| Phase 4 compared to | 30 (−117, 176) | 47 (−54, 149) | 16 (−69, 100) | 33 (−77, 144) |
| LMIC only (n = 6 sites)b | ||||
| Phase 4 compared to | 24 (−41, 89) | 42 (−20, 105) | 13 (−64, 90) | 26 (−27, 80) |
Rates per 100 persons with pulmonary TB, in intervention sites (n = 8) and control sites in main trial. Differences that are significant are in bold.) All countries (Benin, Canada, Ghana, and Indonesia) and in LMIC only (Benin, Ghana, Indonesia.
a
Estimated with marginal model with log link using NLESTIMATE, corrected for clustering.
b
Estimated with marginal model with log link using NLESTIMATE, corrected for clustering, and small clusters.